modelH02AB10
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Cortisone | |
| ATC code: | H02AB10 | route: | oral |
| compartments: | 1 | |
| dosage: | 25 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
Cortisone is a naturally occurring corticosteroid hormone (glucocorticoid) produced by the adrenal cortex. It is used as a replacement therapy for adrenocortical insufficiency (such as Addison's disease) and historically was used for its anti-inflammatory and immunosuppressive properties. Over time, its clinical use has largely been replaced by other synthetic corticosteroids with more favorable pharmacokinetics. It is not commonly used as a first-line therapy today.
Pharmacokinetics
Typical pharmacokinetic parameters estimated for an average adult without specific disease conditions, based on general glucocorticoid pharmacology due to limited direct clinical PK data for cortisone.
References
Giordano, R, et al., & Arvat, E (2014). Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature. European endocrinology 10(1) 75–78. DOI:10.17925/EE.2014.10.01.75 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29872468
Brooker, L, et al., & George, A (2012). Carbon isotope ratio analysis of endogenous glucocorticoid urinary metabolites after cortisone acetate and adrenosterone administration for doping control. Drug testing and analysis 4(12) 951–961. DOI:10.1002/dta.1403 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22987608
Popot, MA, et al., & Cowan, DA (1999). New approaches to detect cortisol administration in the horse. Equine veterinary journal 31(4) 278–284. DOI:10.1111/j.2042-3306.1999.tb03817.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/10454084
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)